Sonidegib
Chemical compound
From Wikipedia, the free encyclopedia
Sonidegib (INN), sold under the brand name Odomzo, is a medication used to treat cancer.[1]
| |
| Clinical data | |
|---|---|
| Trade names | Odomzo |
| Other names | LDE225, erismodegib |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615034 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | <10% |
| Protein binding | >97% |
| Metabolism | Liver (CYP3A) |
| Elimination half-life | ~28 days |
| Excretion | Feces (~70%), urine (30%)[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H26F3N3O3 |
| Molar mass | 485.507 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism).[4][5]
Approvals and indications
It was approved for medical use in the United States and in the European Union in 2015[6][1][7][8]
It is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.[1]
Pharmacology
Sonidegib is administered by mouth. Common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss.[1]
Sonidegib binds to and inhibits smoothened to inhibit activation of the Hedgehog pathway. Sonidegib is primarily metabolized by CYP3A and is eliminated hepatically.[1]
Development
It has been investigated as a potential treatment for:
- Pancreatic cancer[9][10][11][12]
- Breast cancer[13][14]
- Basal cell carcinoma of the skin[15][16][17]
- Small cell lung cancer[18]
- Medulloblastoma[19][20]
- Advanced solid tumors (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme)[21][22][23]
- Acute leukemia[24] and chronic myeloid leukemia[25]
- Myelofibrosis and essential thrombocythaemia[26]
It has demonstrated significant efficacy against melanoma in vitro and in vivo.[27] It also demonstrated efficacy in a mouse model of pancreatic cancer.[28]
